Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab

Immunotherapy. 2020 Oct;12(14):1041-1046. doi: 10.2217/imt-2020-0016. Epub 2020 Aug 18.

Abstract

Aim: We describe a case of an advanced disease non-small-cell lung cancer patient with low PD-L1 expression, but high tumor mutation burden (35 muts/Mb) who developed immune-related hypothyroidism and achieved subsequent partial response, while on clinical trial (NCT03382912) with nivolumab and PEGylated IL-10 (Pegilodecakin, ARMO BioSciences/Eli Lilly and Company, IN, USA). Results/conclusion: Results suggest positive antitumor activity to combination IL-10/nivolumab despite low PD-L1 expression but in likely relationship to high tumor mutation burden and in association with immune-mediated thyroid dysfunction in this case.

Keywords: IL-10; immune-related adverse event; nivolumab; thyroid dysfunction.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung / complications
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Humans
  • Hypothyroidism / complications*
  • Immune Checkpoint Inhibitors / immunology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunity / immunology*
  • Interleukin-10 / therapeutic use*
  • Lung Neoplasms / complications
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Male
  • Nivolumab / immunology
  • Nivolumab / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • Treatment Outcome

Substances

  • Immune Checkpoint Inhibitors
  • pegilodecakin
  • Interleukin-10
  • Nivolumab
  • Polyethylene Glycols

Associated data

  • ClinicalTrials.gov/NCT03382912